Dyadic Logo Current.jpg
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
August 11, 2021 08:35 ET | Dyadic International, Inc.
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...
Dyadic Logo Current.jpg
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
July 27, 2021 08:20 ET | Dyadic International, Inc.
Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III...
Dyadic Logo Current.jpg
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
June 28, 2021 08:30 ET | Dyadic International, Inc.
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and...
PDF to PNG Logo.png
MOMENTA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
August 19, 2020 12:59 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Momenta Pharmaceuticals, Inc. (“Momenta”) (NASDAQ GS: MNTA) regarding possible...
Aleafia Health - Science Seeding Wellness
Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO®
July 24, 2020 07:15 ET | Aleafia Health Inc.
SPRAVATO® (esketamine) nasal spray uses the first new mechanism of action in decades to treat treatment resistant depression disorder Aleafia Health medical clinics along with select physicians and...
BioDelivery Sciences logo
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 21, 2018 08:00 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 21, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences logo
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
August 15, 2018 09:26 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with...
BioDelivery Sciences logo
BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management
July 30, 2018 07:55 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with...
BioDelivery Sciences logo
BioDelivery Sciences to Present at the William Blair 2018 Growth Stock Conference
June 01, 2018 08:00 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading specialty pharmaceutical company in the field of pain management and addiction...
BioDelivery Sciences logo
BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference
May 23, 2018 08:00 ET | BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 23, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine,...